Research in contextEvidence before this studyGut microbiota, especially butyrate-producing bacteria which is involved in anti-inflammation, have been associated with diabetes in general population. Few studies have examined this relationship in HIV-infected individuals who have chronic immune activation and inflammation. Recent evidence from a study of European men (mostly men who have sex with men) showed that HIV-infected individuals with diabetes had reduced microbial composition along with increased tryptophan catabolism which reflects high levels of inflammation and immune activation.Added value of this studyIn the present study, we assessed the associations of gut microbiota and broad spectrum of metabolite profiles with diabetes in minority HIV-infected women and women at high risk for HIV infection. In women with diabetes, we observed reduced abundance of four bacterial genera (*Finegoldia, Anaerococcus, Sneathia,* and *Adlercreutzia*) and increased concentrations of plasma metabolites in tryptophan catabolism, branched-chain amino acid and proline metabolism. Butyrate producing *Anaerococcus* was inversely associated with tryptophan catabolism, providing clues about bacteria-mediated metabolic pathways.Implications of all the available evidenceThis study and previous studies consistently showed altered gut microbiota and related metabolite changes in HIV-infected individuals with diabetes. These data suggest a potential link between reduced butyrate-producing bacteria and increased tryptophan catabolism in the development of diabetes in the context of HIV infection, possibly through inflammation and immune activation.Alt-text: Unlabelled Box

1. Introduction {#s0020}
===============

Metabolic disorders such as insulin resistance and diabetes have been of significant concern in HIV-infected people with successful antiretroviral therapy (ART) \[[@bb0005]\]. Prior studies have shown that excess risk of chronic metabolic disorders in HIV-infected individuals might be due to complicated interactions of chronic HIV infection, long-term ART, factors unrelated to HIV infection, and the underlying inflammatory process. Understanding of this pathophysiology remains incomplete.

Emerging evidence from animal and human studies has suggested an important role of gut microbiota in the development of type 2 diabetes mellitus \[[@bb0010], [@bb0015], [@bb0020], [@bb0025]\]. Multiple observational studies with populations of diverse age, sex, and race/ethnicity suggested that *Roseburia* and *Faecalibacterium prauznitzii* were less abundant in individuals with diabetes, compared to those without diabetes \[[@bb0010],[@bb0015]\]. It has been suggested that butyrate, a short-chain fatty acid produced by *Roseburia* and *F. prauznitzii*, may have a protective effect in the development of type 2 diabetes \[[@bb0030], [@bb0035], [@bb0040]\]. Moreover, previous studies have found that gut microbiota and some related metabolites (e.g., tryptophan-kynurenine metabolites) are altered in HIV-infected individuals \[[@bb0045], [@bb0050], [@bb0055]\], though concomitant influences remain to be unraveled such as HIV infection, low CD4+ T-cell counts, high viral load, ART treatment and sexual behavior \[[@bb0060], [@bb0065], [@bb0070], [@bb0075]\]. Several studies on gut microbiota reported lower bacterial diversity in HIV infected individuals with no ART, low CD4+ counts, or high viral loads \[[@bb0080], [@bb0085], [@bb0090]\]. The higher relative abundance of *Prevotella* in untreated HIV-infected has been observed in multiple studies \[[@bb0065], [@bb0070], [@bb0075]\], while a recent study suggested that the increase in *Prevotella* was associated with sexual preference, men who have sex with men (MSM), but was not driven by HIV infection \[[@bb0060]\].

Although gut microbiota and related metabolites have been implicated in diabetes and HIV infection, few studies have investigated the relationship between gut microbiota and diabetes in the context of HIV infection. One recent study reported that HIV-infected individuals with diabetes had reduced microbial diversity along with increased tryptophan catabolism, endothelial dysfunction and inflammation compared to HIV-infected only and healthy controls \[[@bb0095]\]. However, the majority of the HIV-infected participants included in the study were MSM \[[@bb0095]\] which might have different gut microbiota patterns \[[@bb0060]\]. Therefore, in this study, we aimed to examine the associations of gut microbiota and plasma metabolite profiles with diabetes among HIV-infected women and women with high risk of HIV infection from the Women\'s Interagency HIV Study (WIHS).

2. Methods {#s0025}
==========

2.1. Study participants {#s0030}
-----------------------

The WIHS is an ongoing prospective cohort study established in 1994 to investigate the progression of HIV in women, with a comparison HIV-negative group with high-risk behaviors for HIV infection including injection drug use, sexually transmitted disease, unprotected sex with 3+ men or protected sex with \>5 men, or having exchanged sex for drugs, money, or shelter \[[@bb0100]\]. Details on study design and methods have been described previously \[[@bb0100]\]. Every 6 months, WIHS participants undergo a core visit with a comprehensive physical examination, providing biological specimens, and completing interviewer-administered questionnaires. In this study, 50 women from the WIHS Bronx site provided fecal samples in 2015--2016 and we included 48 samples for analyses, excluding one sample of very low reads in 16S rRNA gene sequencing of the gut microbiome (497 total read counts) and one sample from the sole HIV-infected woman not receiving ART. All individuals provided informed consent, and the studies were approved by the Institutional Review Board of Albert Einstein College of Medicine.

2.2. Fecal sample collection {#s0035}
----------------------------

Fecal samples were collected using a home-based self-collection kit that was distributed to participants during their core WIHS visit. The kit had all of the materials needed, including a pre-addressed envelope that the participants used to return the specimen to our lab at Albert Einstein College of Medicine. Fecal samples were self-collected using a disposable paper in an inverted hat shape that goes over the toilet seat to catch the fecal samples. Fecal samples were deposited in a collection tube containing 4 ml of RNAlater (a nucleic acid stabilizer that preserves the microbiome composition for up to 14 days at room temperature \[[@bb0105]\]) (QIAGEN, Valencia, CA), which was placed into a bag with absorbent/desiccator material and shipped via mail to our lab within 2 days for immediate processing and storage at −80 °C. At the time of fecal sample collection, participants also completed a questionnaire regarding antibiotic use, gastrointestinal medications, commercial probiotics, steroids, drugs stimulating or suppressing immune system in the last 6 months.

3. DNA extraction, PCR amplification and high-throughput sequencing {#s0040}
===================================================================

Genomic DNA was extracted with the DNeasy PowerLyzer PowerSoil DNA Isolation Kit (QIAGEN, Valencia, CA), following the manufacturer\'s instructions. PCR amplification was performed on the 16S rRNA gene V4 hypervariable region using the primers 16SV4_515F (GTGYCAGCMGCCGCGGTA) and 16SV4_806R (GGACTACHVGGGTWTCTAAT), with a 12-bp unique Golay barcoding \[[@bb0110],[@bb0115]\]. PCR reactions were performed with an initial denaturation of 95 °C for 5 min, followed by 15 cycles of 95 °C for 1 min, 55 °C for 1 min, and 68 °C for 1 min, followed by 15 cycles of 95 °C for 1 min, 60 °C for 1 min, and 68 °C for 1 min, a final extension for 10 min at 68 °C on a GeneAmp PCR System 9700 (Applied Biosystems, Foster City, CA). The PCR products were purified using a QIAquick Gel Extraction Kit (QIAGEN) and quantified using a Qubit 2.0 Fluorometic High Sensitivity dsDNA Assay (Life Technologies). KAPA LTP Library Preparation Kit (KAPA Biosystems, Wilmington, MA) was used on the purified PCR products according to the manufacturer\'s protocol and the size integrity of the amplicon with Illumina indices was validated with a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA) at the Genomics Core at Albert Einstein College of Medicine. High-throughput amplicon sequencing was conducted on a MiSeq (Illumina, San Diego, CA. RRID:[SCR_016379](rridsoftware:SCR_016379){#ir0005}) using 2 × 300 paired-end fragments at the Albert Einstein College of Medicine Sequencing Core.

4. Bioinformatics analysis {#s0045}
==========================

Illumina reads were preprocessed to remove bases that fell below PHRED quality score of 25 using prinseq \[[@bb0120]\]. Processed reads were then demultiplexed using sample specific barcode combinations using novobarcode \[[@bb0125]\]. Paired end reads were merged using pandaseq with default settings \[[@bb0130]\]. OTU clustering and quality filtering was performed using the Quantitative Insights Into Microbial Ecology (QIIME) software package, version 1.9 \[[@bb0135]\]. USEARCH \[[@bb0140]\] was used to remove sequencing noise and sequence chimeras. Sequences were demultiplexed and clustered into operational taxonomic units (OTUs) with a minimum cluster similarity of 97% using UCLUST \[[@bb0140]\]. Sequences were assigned using UCLUST with the Greengenes 13.8 microbial database \[[@bb0145]\]. The resulting *biom* table was rarefied to 7500 reads per sample and statistical analyses were performed after collapsing OTUs at the genus level. To characterize functional contents of microbiota, PICRUSt was implemented to predict the abundance of KEGG orthologs \[[@bb0150]\] and the butyrate pathway in KEGG was visualized to be integrated with differential abundance by diabetes status using R/pathview \[[@bb0155],[@bb0160]\].

5. Targeted metabolomics analysis {#s0050}
=================================

Blood was drawn into CPT tube containing sodium citrate as anticoagulant at least 8 h of fasting at the core WIHS visit. The tube was gently inverted 8 times at room temperature and centrifuged at 1500*g* for 20 min within 6 h of blood draw. The plasma aliquot was stored at −80 °C. Targeted metabolomics profiling were performed on stored frozen plasma specimens that had been collected at the semiannual core study visit closest to the stool sample collection, using the AbsoluteIDQ p180 kit (BIOCRATES Life Sciences AG, Innsbruck, Austria). This targeted method simultaneously measures 188 metabolites with liquid chromatography and flow injection analysis-mass spectrometry, and the detailed assay procedures have been described previously \[[@bb0165],[@bb0170]\]. The current analysis included 130 metabolites, passing the quality control criteria of coefficient of variation \<30% and low rate of out of detection range (25%): 20 amino acids, 6 biogenic amines, 12 acylcarnitines, 78 glycerophospholipids, and 14 sphingolipids.

6. Assessment of HIV infection, diabetes, and other variables {#s0055}
=============================================================

Demographic, clinical, and laboratory variables were collected using standardized protocols at semi-annual core study visits \[[@bb0175]\]. HIV infection was ascertained by enzyme-linked immunosorbent assay and confirmed by Western blot. HIV-specific parameters included CD4+ T-cell counts, HIV-1 viral load, and detailed information on ART. Diabetes was defined based upon standardized data from semiannual visits: fasting plasma glucose ≥126 mg/dl, HbA1C ≥6.5%, or self-report of diabetes medication use.

7. Data statement {#s0060}
=================

The datasets analyzed in the current study are not publicly available but are available upon request after approval from the WIHS.

7.1. Statistical analysis {#s0065}
-------------------------

Characteristics of the study sample by diabetes status and HIV serostatus were summarized as counts and percentages for categorical variables, and medians and interquartile ranges for continuous variables. The characteristics were compared by diabetes status or HIV serostatus using the Fisher\'s exact test for categorical variables and the Mann-Whitney *U* test for continuous variables. The α-diversity of microbiota was performed using three measures (observed richness at the OTU level, Chao 1 index and Shannon index in the genus level) and each was compared by diabetes status in a linear regression adjusting for age and HIV status. β-diversity measures (Bray-Curtis, unweighted UniFrac \[[@bb0180]\], and weighted UniFrac \[[@bb0185]\]) were estimated for dissimilarity of microbial community compositions between samples. Principal coordinates analysis (PCoA) for β-diversity was used to examine the clusters of samples by diabetes status and HIV serostatus. Permutational multivariate ANOVA (PerMANOVA) was performed to test the association of β-diversity with diabetes, adjusting for age and HIV serostatus. The differential abundance of each genus or upper hierarchy by diabetes was tested using a linear regression on arcsin transformed relative abundance, adjusting for age and HIV status or adjusting for age stratified by HIV status. False discovery rate corrected *P*-value was calculated using Benjamini and Hochberg\'s method \[[@bb0190]\]. The metabolite concentration by diabetes status was tested using the Mann-Whitney *U* test and the Spearman correlation between metabolites and relative abundance of genus was calculated. Predicted relative abundance of KEGG orthologs by PICRUSt was compared by diabetes status using *t*-test. All statistical tests were two-sided and were conducted using R (version 3.3.2) \[[@bb0195]\] with the *phyloseq* \[[@bb0200]\] and *vegan* \[[@bb0205]\] packages.

8. Results {#s0070}
==========

8.1. Characteristics of study population {#s0075}
----------------------------------------

[Table 1](#t0005){ref-type="table"} shows the characteristics of study participants by diabetes status and HIV serostatus. There was no significant difference in race/ethnicity by diabetes status and HIV serostatus. Women with diabetes tended to be older (*P* = .06 \[Mann-Whitney *U* test\]) and have higher BMI (*P* = .06 \[Mann-Whitney U test\]) among HIV-uninfected women. For glycemic traits, women with diabetes tended to have higher glucose and hemoglobin A1c levels irrespective of HIV serostatus. Half of women with diabetes took antidiabetic medications, mostly metformin (8 out of 11). Antibiotic use in the past 6 months was more frequent among HIV-infected women compared to HIV-uninfected women (*P* = .06 \[Fisher\'s exact test\]). All the HIV-infected participants were currently receiving highly active ART, and HIV-infected participants with diabetes were taking ART longer than the HIV-infected women without diabetes (*P* = .006 \[Fisher\'s exact test\]). Most HIV-infected women (25/28) had suppressed viral load (\< 40 copies/ml) and high CD4 counts (24 women with \>500 counts). There were no significant differences in CD4 counts and viral load between women with and without diabetes (*P* \> .13 \[Mann-Whitney *U* test\]).Table 1Characteristics of study subjects with diabetes and without diabetes.Table 1HIV+HIV-DiabetesNo DiabetesDiabetesNo DiabetesNumber of individuals1612614Age52 (51--55)51 (42--60)53 (52--57)49 (42--51)Race Black11 (69)8 (67)2 (33)10 (71) Hispanic3 (19)1 (8)2 (33)3 (21) Other2 (13)3 (25)2 (33)1 (7)BMI (kg/m^2^)32 (30--38)31 (27--37)33 (33--37)26 (22−32)Antibiotic10 (71)6 (55)1 (25)4 (33)Any antidiabetic medication7 (43.8)--4 (66.7)--Glucose (mg/dl)105 (94--115)96 (87--105)109 (96--124)94 (88--99)Hemoglobin A1C (%)6.2 (6.0--6.5)5.8 (5.7--6.0)6.3 (5.9--6.8)5.6 (5.5--5.8)Hepatitis C infection5 (31)3 (25)2 (33)1 (7)  HIV-specific characteristicsCurrent ART16 (100)12 (100)----Cumulative years of ART12.5 (8.0--15.9)4.8 (3.9--9.6)----CD4 counts810 (629--1124)678 (578--955)----Viral load (copies/ml)\<20 (20--30.2)\<20 (20−20)----Undetectable viral load (≤20 copies/ml)10 (62.5)11 (91.7)----[^1]

8.2. Comparisons of microbial diversity and composition {#s0080}
-------------------------------------------------------

A total of 1084 operational taxonomic units (OTUs) were found with a 97% similarity cutoff, after rarefication at 7500 counts. At the phylum level, *Firmicutes, Bacteroidetes, Actinobacteria,* and *Fusobacteria* were found in all participants, having median microbial abundances of 52%, 35%, 2.9%, and 0.8%, respectively (Fig. S1). At the genus level, 147 genera were identified with median relative abundance of 0.43% (IQR = 0.1--0.88%), and 91 genera showed at least 0.1% average relative abundance.

The microbiota profiles of our sample population were ordinated by principal coordinate analysis (PCoA) with the Bray-Curtis dissimilarity at genus level. The plot of the first and second principal coordinates in [Fig. 1](#f0005){ref-type="fig"}(a), explaining 15.2% and 8.7% of the total variance, showed no separation by diabetes status or HIV serostatus. In addition, PerMANOVA tests based on various sample-to-sample distances (Bray-Curtis, unweighted and weighted UniFrac) found no significant differences in microbiota profiles by age, HIV serostatus, diabetes status, or metformin use (all *P* \> .10, R^2^ \< 0.04, Table S1). Significant differences in Bray-Curtis dissimilarity and weighted UniFrac were observed by antibiotic use (*P* = .05, 0.01, Table S1, Fig. S2). The within-sample microbial diversity for each measure (observed OTU richness, Chao 1 index and Shannon index in genus level) was not significantly different by age, HIV, diabetes, antibiotic use, or metformin use (all *P* \> .12 \[linear regression\], [Fig. 1](#f0005){ref-type="fig"}(b), Table S2).Fig. 1Microbial composition and diversity by HIV serostatus and diabetes (a) Principal coordinates analysis of Bray-Curtis dissimilarity of microbiota by HIV serostatus and diabetes, (b) Alpha diversity of microbiota by HIV serostatus and diabetes. Observed richness is in the OTU level, and Chao 1 and Shannon index are in the genus level. A bar represents a median of the group.Fig. 1

8.3. Differentially abundant genera by diabetes {#s0085}
-----------------------------------------------

The differential abundance analysis identified four genera (*Finegoldia, Anaerococcus, Sneathia,* and *Adlercreutzia*) that were significantly associated with diabetes status (*P* \< .05; FDR corrected *P*-value \<.1 for *Finegoldia and Anaerococcus.* [Table 2](#t0010){ref-type="table"}). These analyses adjusted for HIV status and age, examining 91 genera with at least 0.01% average relative abundance. These four differentially abundant genera were less abundant in women with diabetes compared to those without diabetes ([Fig. 2](#f0010){ref-type="fig"}). The four genera did not show statistically significant associations with HIV serostatus (Table S3). In the analysis stratified by HIV status ([Table 2](#t0010){ref-type="table"}), *Finegoldia* and *Anaerococcus* showed significantly inverse association with diabetes in both HIV-infected and HIV-uninfected women, whereas there were suggestive but non-significant interactions between HIV infection and diabetes in relation to *Sneathia* and *Adlercreutzia* (*P*~HIV×Diabetes~ = .09, 0.06, respectively). For those four genera that were differentially abundant by diabetes, we further examined the potential influences of antidiabetic medication use, antibiotic use and hepatitis C infection. No significant associations of four genera with these factors were observed (Table S4-S6), except for *Sneathia* which showed a nominal significant association with antibiotic use (Table S6). Sensitivity analyses indicated that the four genera exhibited consistent associations with diabetes after excluding the women with antibiotic use, metformin use, or hepatitis C infection, respectively, or adjusting for antibiotic use or hepatitis C infection (Table S7-S8).Table 2Differentially abundant genera by diabetes status.Table 2FamilyGenusAll[a](#tf0005){ref-type="table-fn"}HIV+HIV-*P*~HIV×Diabetes~[c](#tf0015){ref-type="table-fn"}β (SE)*P*β (SE)*P*β (SE)*P*Tissierellaceae*Finegoldia*−0.010 (0.003)\<0.001[b](#tf0010){ref-type="table-fn"}−0.013 (0.004)0.003−0.005 (0.002)0.0380.133Peptoniphilaceae*Anaerococcus*−0.012 (0.004)0.002[b](#tf0010){ref-type="table-fn"}−0.012 (0.005)0.026−0.012 (0.005)0.0390.967Leptotrichiaceae*Sneathia*−0.015 (0.005)0.010−0.022 (0.008)0.015−0.002 (0.004)0.6010.090Coriobacteriaceae*Adlercreutzia*−0.008 (0.003)0.010−0.004 (0.003)0.287−0.016 (0.005)0.0090.057[^2][^3][^4][^5]Fig. 2Relative abundance of four bacterial genera by diabetes status. A bar represents the mean relative abundances and an error bar represents 1 standard error of relative abundances. The topmost *P*-value is the significance level of differential abundances between the women with diabetes and without diabetes, tested by a linear regression adjusting for age and HIV serostatus, and *P*-values in the second line are the significance levels of differential abundances between the women with diabetes and without diabetes, tested by linear regressions adjusting for age among HIV+ (left) and among HIV- (right).Fig. 2

8.4. Associations of metabolites with diabetes and bacterial genera {#s0090}
-------------------------------------------------------------------

Plasma levels of 12 metabolites showed nominal significant associations with diabetes status (*P* \< .05 \[Mann-Whitney *U* test\]; all FDR corrected *P*-value \>.1. [Fig. 3](#f0015){ref-type="fig"}). In the women with diabetes compared to those without diabetes, we found higher concentrations of seven amino acids or biogenic amines (kynurenine/tryptophan ratio as a marker for kynurenine pathway activation, ADMA, proline, alanine, isoleucine, leucine, and valine) and elevated valerylcarnitine in acylcarnitines classes, while octadecadienylcarnitine in acylcarnitines and three glycerophospholipids (PC ae C34:3, PC ae C36:5 and PC ae C38:5) showed lower concentrations. To further investigate the engagement between metabolites and gut microbiome in relation to diabetes, we examined the correlations between the four diabetes-associated gut microbial genera and these 12 metabolites (Fig. S3). *Anaerococcus* was inversely correlated with kynurenine/tryptophan ratio and valine (*r* = −0.38, −0.3, *P* = .007, 0.04 \[*P*-value for Spearman correlation\]), and *Adlercreutzia* was inversely correlated with proline and alanine (*r* = −0.37, −0.32, *P* = .01, 0.03 \[*P*-value for Spearman correlation\]). On the other hand, all four diabetes-associated microbial genera showed some positive correlations with diabetes-associated glycerophospholipids (*r* = 0.12--0.36 for all three glycerophospholipids and *r* = 0.29--0.36 with *P* \> .05 \[*P*-value for Spearman correlation\]). Across all metabolites, four diabetes-associated microbial genera tended to be positively correlated with glycerophospholipids (Fig. S4), though it should be noted that these glycerophospholipids are highly correlated with each other.Fig. 3Metabolic concentration levels by diabetes status. A bar represents the mean concentrations (ratio for kynurenine/tryptophan ratio) and an error bar represents 1 standard error of concentrations (ratio for kynurenine/tryptophan ratio). The topmost P-value is the significance level of differential concentrations between the women with diabetes and without diabetes \[Mann-Whitney *U* test\], and *P*-values in the second line are the significance levels of differential concentrations between the women with diabetes and without diabetes \[Mann-Whitney U test\], among HIV+ (left) and among HIV- (right). All P for interaction of diabetes status and HIV serostatus \>.18 \[linear regression\].Fig. 3

Of the pathways involved with the aforementioned metabolites, we then compared the microbial functional contents related to the pathways, predicted by PICRUSt, between women with diabetes and without diabetes (Table S9). Only Enoyl-CoA hydratase in butyrate pathway (K01692) and carbamoyl-phosphate synthase (K01955) in alanine, aspartate and glutamate metabolism showed nominally significant differences (*P* = .03, 0.006 \[*t*-test\]). In the butyrate pathway, a higher proportion of enzymes were decreased in diabetes, but most enzymes did not show statistically significant differences (Fig. S5).

9. Discussion {#s0095}
=============

In this study of women with, or at high risk for HIV infection, we found no significant differences in the composition and the diversity of microbial communities between women with and without diabetes. These findings are generally consistent with most previous studies that examined the relationship between gut microbiota and diabetes in HIV-uninfected populations \[[@bb0010],[@bb0210],[@bb0215]\]. When examining HIV infection in relation to microbial diversity, our study did not find significant associations, while many previous studies found such differences by HIV infection to be statistically significant \[[@bb0060],[@bb0065],[@bb0080]\]. However, it should be noted that most previously reported alterations in microbial diversity were observed in newly HIV-infected, untreated patients, or MSM, compared to HIV-uninfected controls \[[@bb0060],[@bb0080],[@bb0095]\]. In our study, participants had long standing HIV-infection and ART use. Consistent with this, a prior study reported that individuals with chronic untreated HIV infection, but not those under long-term ART, had greater overall microbial diversity compared to HIV negative controls \[[@bb0070]\]. Another study comparing HIV-infected individuals who were receiving suppressive ART with HIV-uninfected individuals found no significant differences in alpha-diversity although clustering in beta-diversity was observed \[[@bb0220]\]. It still remains unclear how chronic HIV infection and long-term ART use influence overall gut microbial diversity.

At the genus level, we found that relative abundances of two genera, *Finegoldia* and *Anaerococcus,* were significantly lower in women with diabetes compared to those without diabetes, and the results were consistent for HIV-infected and HIV-uninfected individuals. Although there was little direct a priori evidence linking *Finegoldia* and *Anaerococcus* with diabetes, *Anaerococcus* is known to produce butyrate, a product of bacterial fermentation, which is involved in anti-inflammation, insulin sensitivity improvement, and diabetes amelioration \[[@bb0225], [@bb0230], [@bb0235]\]. The potential involvement of *Anaerococcus* in anti-inflammation is further supported by our results showing an inverse correlation between *Anaerococcus* and kynurenine/tryptophan ratio, an indicator of tryptophan catabolism. Tryptophan is catabolized into kynurenine through indoleamine 2,3-dioxygenase (IDO) which is an enzyme induced in many types of immune cells in response to inflammation and immune activation, while transcription of IDO can be down-regulated by sodium butyrate \[[@bb0050],[@bb0240], [@bb0245], [@bb0250], [@bb0255]\]. In our study, we also found higher kynurenine/tryptophan ratio in diabetes, which is consistent with previous findings \[[@bb0095]\].

Indeed, two butyrate-producing gut microbes, *Faecalibacterium* and *Roseburia*, have been reported to be decreased in people with diabetes \[[@bb0010],[@bb0015]\], and *Roseburia* was lower in metformin-untreated people with diabetes compared to those without diabetes \[[@bb0020]\]. In our study, we observed that *Faecalibacterium* was marginally reduced in women with diabetes (*P* = .07 \[linear regression\]), but *Roseburia* did not differ by diabetes status (*P* = .53 \[linear regression\]). In addition, PICRUSt analysis revealed a higher proportion of enzymes homologous to those for butyrate metabolism which were decreased in diabetes, although most of these orthologs did not show statistically significant differences, given the relatively small sample size of current analysis. In addition, a previous study reported beneficial effects on glucose metabolism by transplanting butyrate-producing bacteria *Clostridium butyricum* CGMCC0313.1 to diabetes mouse models \[[@bb0260]\]. These data suggest a beneficial role of butyrate-producing gut microbes in patients with diabetes. Further investigation is needed to examine the butyrate-producing microbes observed in this study (e.g., *Anaerococcus*) and their relationships with diabetes, especially in HIV-infected individuals.

In addition, another two genera, *Sneathia* and *Adlercreutzia,* showed suggestive inverse associations with diabetes in our study, with potential effect modifications by HIV infection. Interestingly, the HIV+ group without diabetes showed significantly higher relative abundance of *Sneathia* while the other three HIV/diabetes status groups showed lower and similar relative abundance of this genus. This may help illustrate why the inverse association between *Sneathia* and diabetes has been observed only in HIV+ groups. The genus *Sneathia* is one of the bacteria transmitted during vaginal delivery \[[@bb0265]\] and the disruption of natural transmission of the maternal microbiome to the newborn may be associated with type 1 diabetes, asthma, and obesity \[[@bb0270], [@bb0275], [@bb0280], [@bb0285]\]. However, no previous studies have examined the relationship between HIV infection and *Sneathia*. Our study suggested an inverse association between the *Adlercreutzia* genus and diabetes in HIV-uninfected individuals, while a previous study reported that the *Adlercreutzia* genus was decreased in fecal samples of HIV infected individuals with diabetes, compared to healthy controls and those with HIV infection only \[[@bb0095]\]. Although the potential effect modification by HIV infection needs further investigation, the suggestive association between *Adlercreutzia* and diabetes was supported by the inverse correlation between this genus and plasma proline observed in this study, elevated proline levels associated with diabetes in this and other studies \[[@bb0290],[@bb0295]\] and potential involvement of this genus in the peroxisome proliferator-activated receptor gamma (PPAR-gamma) pathway \[[@bb0300], [@bb0305], [@bb0310]\]. However, our results should be interpreted with caution, because of the relatively small sample size. Future studies with larger sample sizes are warranted to clarify the associations between these genera and diabetes in the context of HIV infection.

One unique feature of this current study is the inclusion of women either with HIV-infection or at high risk for HIV-infection, who were of African American (65%) or Hispanic (29%) racial/ethnic backgrounds. Previous studies of the gut microbiota and diabetes focused primarily on Europeans or Chinese without HIV-infection \[[@bb0010], [@bb0015], [@bb0020]\]. The participants in a previous study on diabetes with HIV infection were Europeans, mostly men (88%) and MSM (75%), and had a relatively shorter time on stable ART (25.4 months (IQR = 13.2--37.7) for HIV infected with diabetes). Prior healthy control groups included convenience samples such as hospital staff, unlike our comparison group comprising a population based sample at high risk for HIV-infection \[[@bb0095]\]. In addition, dietary choices, access to health care, and overall health status of our study participants might be different from other studies due to demographic differences and exposure to HIV-infection \[[@bb0315]\]. These factors may influence microbiota compositions in relation to diabetes. HIV infection, including effective viral suppression by ART, might contribute to microbial dysbiosis, affecting the disruption of immune response and resulting in increased morbidity and mortality \[[@bb0030],[@bb0045],[@bb0065],[@bb0320]\].

Our study has several limitations. The sample size is relatively small and multiple tests were performed in this study, and only two significant genera passed FDR correction. In the metabolomics analysis, although the associations between metabolites and diabetes did not pass FDR correction, many significant metabolites observed in our study (e.g. kynurenine/tryptophan ratio \[[@bb0095]\], branched-chain amino acids \[[@bb0325]\], proline \[[@bb0290],[@bb0295]\]) have been previously reported to be associated with diabetes in HIV or non HIV populations. Thus, these results are unlikely to be false positive findings. In addition, our study did not collect information on dietary intake which has been closely related to the microbial communities \[[@bb0330], [@bb0335], [@bb0340]\]. Our plasma metabolomics does not cover the full spectrum of metabolites and especially short chain fatty acids were not measured (e.g., butyric acid). In addition, due to high sodium sulfate content in the samples collected with RNAlater, our fecal samples were not useful for metabolomics assay \[[@bb0345]\].

In summary, this study suggests decreased relative abundances of four gut microbial genera and related metabolite changes associated with diabetes in women with, or at high risk for HIV-infection. In particular, a known butyrate-producing bacterial genus had lower relative abundance, correlating with higher tryptophan catabolism, in diabetes. These findings suggest a potential interrelationship between gut microbiota, diabetes and HIV infection through inflammation and immune activation. Further studies with larger sample sizes and metagenomics data are needed to investigate specific microbes and their functional role in diabetes along with metabolic profiles in the context of HIV-infection.
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[^1]: Data are presented as count (%) for categorical variables or median (IQR) for continuous variables.

[^2]: Data are adjusted for age.

[^3]: Additionally adjusted for HIV serostatus.

[^4]: FDR corrected *P*-value \<.1.

[^5]: P for interaction by HIV serostatus on the association with diabetes status.
